Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 53.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 148,568 shares of the company's stock after selling 169,826 shares during the period. ExodusPoint Capital Management LP owned approximately 0.17% of Syndax Pharmaceuticals worth $1,964,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. State Street Corp lifted its holdings in shares of Syndax Pharmaceuticals by 4.1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock valued at $72,588,000 after purchasing an additional 148,491 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares during the last quarter. Geode Capital Management LLC raised its position in Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after acquiring an additional 66,459 shares during the period. Franklin Resources Inc. boosted its stake in shares of Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after acquiring an additional 208,043 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Syndax Pharmaceuticals by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company's stock valued at $9,318,000 after acquiring an additional 8,876 shares during the period.

Remove Ads

Analysts Set New Price Targets

Several research firms have commented on SNDX. HC Wainwright reissued a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Scotiabank decreased their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Thursday. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.20.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock traded up $0.12 during midday trading on Monday, hitting $11.28. 196,514 shares of the company were exchanged, compared to its average volume of 1,568,908. The firm has a market capitalization of $970.58 million, a PE ratio of -3.11 and a beta of 1.28. The business has a fifty day simple moving average of $13.66 and a two-hundred day simple moving average of $15.31. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the transaction, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,683 shares of company stock worth $336,087 over the last three months. Insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).